Old Web
English
Sign In
Acemap
>
authorDetail
>
Luke Chung
Luke Chung
Sanofi S.A.
Medicine
Alemtuzumab
Internal medicine
Oncology
Neurofilament
4
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)
2021
Neurology
Gavin Giovannoni
Aaron Boster
Regina Berkovich
Krzysztof Selmaj
Luke Chung
Debora Shiota
Salman Afsar
Show All
Source
Cite
Save
Citations (1)
Improved Outcomes With Alemtuzumab Following Switch From SC IFNB-1a: 6-Year Follow-up of CARE-MS II Patients With Active RRMS (TOPAZ Study)
2019
Carolina Ionete
Maria Pia Amato
Michael H. Barnett
Aaron Boster
Dominique Dive
Donna Graves
William David Honeycutt
Christopher LaGanke
Richard A.L. Macdonell
Xavier Montalban
Kunio Nakamura
Celia Oreja-Guevara
David Rog
Bernard M. J. Uitdehaag
Luke Chung
Nadia Daizadeh
S. Afsar
Anthony Traboulsee
Show All
Source
Cite
Save
Citations (0)
Alemtuzumab Treatment Reduces Serum Neurofilament to Levels Comparable With Healthy Controls More Effectively Than SC IFNb-1a: CARE-MS I
2019
Evis Havari
Nadia Daizadeh
Christian Barro
Zuzanna Michalak
David Leppert
Jean Godin
Srinivas Shankara
Luke Chung
Nora Roesch
Carina Kaiser
Tarek A Samad
Alan Jacobs
Ludwig Kappos
Jens Kuhle
Show All
Source
Cite
Save
Citations (0)
Pregnancy Outcomes in Alemtuzumab-treated Patients With RRMS in the Phase 2 and 3 Clinical Development Program Over 16 Years
2019
Jiwon Oh
Elizabeth G Celius
Christina D. Chambers
Joy Derwenskus
Virginia Devonshire
Kerstin Hellwig
George J. Hutton
Pamela A. McCombe
Marie Moore
David Rog
Jean-Raphael Schneider
Lívia Sousa
Stephen G. Vincent
Luke Chung
Nadia Daizadeh
D Alastair S Compston
Show All
Source
Cite
Save
Citations (0)
1